Claims

[Claim 1] A pharmaceutical composition for the prevention and treatment of a cardiovascular disease which comprises lercanidipine hydrochloride and valsartan as active components.

[Claim 2] The composition according to claim 1, wherein the lercanidipine hydrochloride and valsartan are in a separated form.

[Claim 3] The composition according to claim 2, which is prepared by separate granulations of the lercanidipine hydrochloride and valsartan.

[Claim 4] The composition according to claim 3, wherein each of the lercanidipine hydrochloride granules and valsartan granules further comprise a pharmaceutically acceptable excipient.

[Claim 5] The composition according to claim 4, wherein the lercanidipine hydrochloride granules comprise 4 to 10 parts by weight of a pharmaceutically acceptable excipient per 1 part by weight of lercanidipine hydrochloride.

[Claim 6] The composition according to claim 4, wherein the valsartan granules comprise 1 to 2 parts by weight of a pharmaceutically acceptable excipient per 1 part by weight of valsartan.

[Claim 7] The composition according to claim 4, which comprises the combination of 10 mg of lercanidipine hydrochloride and 80 mg of valsartan, 10 mg of lercanidipine hydrochloride and 160 mg of valsartan, 20 mg of lercanidipine hydrochloride and 80 mg of valsartan, or 20 mg of lercanidipine hydrochloride and 160 mg of valsartan.

[Claim 8] The composition according to claim 2, wherein each of the lercanidipine hydrochloride and valsartan is included in a separated layer.

[Claim 9] The composition according to claim 8, wherein a separation layer is placed between the lercanidipine hydrochloride layer and the valsartan layer.

[Claim 10] The composition according to claim 2, which is prepared by coating a valsartan-containing tablet with a lercanidipine hydrochloride-containing layer.

[Claim 11] The composition according to claim 10, wherein a separation layer is placed between the valsartan-containing tablet and the lercanidipine hydrochloride-containing layer.

[Claim 12] The composition according to claim 1, wherein the cardiovascular disease is at least one selected from the group consisting of angina pectoris, hypertension, arteriospasm, cardiac arrhythmia, cardiac hy-

pertrophy, cerebral infarction, congestive heart failure and myocardial infarction.

[Claim 13] A method for the preparation of the composition according to claim 3, which comprises the steps of:

(a) wet-granulating a mixture of lercanidipine hydrochloride and a pharmaceutically acceptable excipient and drying the granules;

(b) wet-granulating a mixture of valsartan and a pharmaceutically acceptable excipient and drying the granules; and

(c) mixing the dried granules prepared in steps (a) and (b).

Claims

1. A pharmaceutical composition for the prevention and treatment of a cardiovascular disease which comprises lercanidipine hydrochloride and valsartan as active components,
   wherein the lercanidipine hydrochloride and valsartan are in a separated form by mixing dried granules of the lercanidipine hydrochloride and valsartan which are prepared separately.

2. The composition according to claim 1, wherein each of the lercanidipine hydrochloride granules and valsartan granules further comprise a pharmaceutically acceptable excipient.

3. The composition according to claim 2, wherein the lercanidipine hydrochloride granules comprise 4 to 10 parts by weight of a pharmaceutically acceptable excipient per 1 part by weight of lercanidipine hydrochloride.

4. The composition according to claim 2, wherein the valsartan granules comprise 1 to 2 parts by weight of a pharmaceutically acceptable excipient per 1 part by weight of valsartan.

5. The composition according to claim 2, which comprises the combination of 10 mg of lercanidipine hydrochloride and 80 mg of valsartan, 10 mg of lercanidipine hydrochloride and 160 mg of valsartan, 20 mg of lercanidipine hydrochloride and 80 mg of valsartan, or 20 mg of lercanidipine hydrochloride and 160 mg of valsartan.

6. The composition according to claim 1, wherein each of the lercanidipine hydrochloride and valsartan is included in a separated layer.

7. The composition according to claim 6, wherein a separation layer is placed between the lercanidipine hydrochloride layer and the valsartan layer.

8. The composition according to claim 1, wherein the cardiovascular disease is at least one selected from the group consisting of angina pectoris, hypertension, arteriospasm, cardiac arrhythmia, cardiac hypertrophy, cerebral infarction, congestive heart failure and myocardial infarction.

9. A method for the preparation of the composition according to claim 1, which comprises the steps of:
   (a) wet-granulating a mixture of lercanidipine hydrochloride and a pharmaceutically acceptable excipient and drying the granules;
   (b) wet-granulating a mixture of valsartan and a pharmaceutically acceptable excipient and drying the granules; and
   (c) mixing the dried granules prepared in steps (a) and (b).